PTC Therapeutics, Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2014. Unaudited financial statements. PTC is a clinical-stage biopharmaceutical company developing small-molecule medicines; its lead candidate, Translarna (ataluren), received conditional European authorization in August 2014 for ambulatory patients aged five or older with nonsense-mutation Duchenne muscular dystrophy (nmDMD).
Financial performance
Amounts below are in millions of dollars, except per-share data. The filing presents no separate gross-profit or gross-margin measure.
| Metric | Three months 2014 | Three months 2013 | Nine months 2014 | Nine months 2013 |
|---|---|---|---|---|
| Total revenue | $1.694 | $16.289 | $12.587 | $30.285 |
| Research and development | $18.765 | $13.886 | $52.967 | $39.855 |
| General and administrative | $10.530 | $6.679 | $26.803 | $17.735 |
| Operating loss | $(27.601) | $(4.276) | $(67.183) | $(27.305) |
| Net loss | $(27.282) | $(4.416) | $(66.484) | $(33.688) |
| Net loss per share | $(0.93) | $(0.19) | $(2.34) | $(5.40) |
- 2014 product sales were $81,000 for both the quarter and nine-month period, from reimbursed early-access programs. The company said it did not expect significant nmDMD commercial revenue in fiscal 2014.
- Collaboration revenue was $716,000 in Q3 and $11.280 million for nine months; grant revenue was $897,000 and $1.226 million, respectively.
- Operating cash use was $49.281 million for nine months, versus $32.459 million in 2013. Investing cash use was $31.983 million, primarily net purchases of marketable securities; financing provided $118.723 million, primarily from the February follow-on offering.
- At September 30, cash and cash equivalents were $52.873 million and marketable securities were $156.516 million, totaling $209.389 million. Current assets were $213.516 million; current liabilities were $17.262 million. Stockholders’ equity was $201.296 million.
- The balance sheet reported no current portion of long-term debt at September 30; the company said prior debt was paid off in July 2013. Other long-term liabilities were $2.237 million.
Changes and notable items
- Q3 revenue fell 90% year over year and nine-month revenue fell 58%. The principal comparison effect was a $10 million Roche SMA milestone recognized in Q3 2013; 2014 collaboration revenue also included a $7.5 million milestone recognized in Q1 following initiation of the SMA Phase 1 program.
- R&D expense increased 35% in Q3 and 33% for nine months, reflecting clinical-trial, manufacturing and regulatory activity and higher share-based compensation. G&A expense increased 57% and 51%, respectively, as commercial-launch and international-infrastructure costs grew.
- Q3 2013 and 2014 losses were affected by different operating and revenue levels. For the nine-month 2013 comparison, net loss attributable to common stockholders also included an $18.249 million deemed dividend and a $3.391 million recapitalization gain; these items did not recur in 2014.
- On October 16, 2014, after quarter-end, PTC completed a 3.45 million-share offering at $36.25 per share, receiving approximately $117.5 million net. This subsequent financing was not included in September 30 cash and securities.
Outlook, risks and contingencies
- Management estimated that cash, investments, offering proceeds and expected collaboration research funding would fund operations and capital expenditures through late 2017. This is an estimate based on assumptions; the company warned it could use funds sooner than expected.
- Management expected significant increases in commercialization, infrastructure and development spending. Planned milestones included a Germany launch within months, further European launches during 2015 and beyond subject to local market access, a rolling U.S. NDA submission for nmDMD before year-end 2014, and initial ACT DMD Phase 3 data in Q4 2015. ACT DMD enrollment was complete. ACT CF enrollment was expected to complete in the second half of 2015, with top-line results about a year later; an EMA application for nmCF was contemplated for mid-2015. A Phase 2 nmMPS I study and PTC596 Phase 1 study were also planned.
- The EEA authorization for nmDMD is conditional, limited by its patient label and subject to annual review; completing ACT DMD and maintaining a positive benefit-risk assessment are important to continuation. PTC disclosed substantial uncertainty around clinical outcomes, regulatory decisions, pricing and reimbursement, patient identification, manufacturing, competition and further funding needs.
- Earlier Translarna trials in nmDMD and nmCF did not meet their primary efficacy endpoints at the prespecified statistical significance level. The company’s supportive interpretations included retrospective and subgroup analyses, which regulators may view as less persuasive. FDA and EMA positions on ACT CF design were not fully aligned.
- PTC described prior clinical observations including modest liver-enzyme elevations in a Phase 1 study and renal adverse events/creatinine elevations in an nmCF trial, associated in some cases with certain antibiotics. It also disclosed EMA GCP inspection findings involving trial eligibility waivers, site oversight and documentation, and said corrective actions had been proposed.
- Other disclosed exposures include contingent Wellcome Trust development/regulatory milestones of up to $68.9 million plus potential royalties, potential SMA Foundation royalties or license-related payments, and $4.473 million in operating lease obligations. Ordinary-course patient-access and clinical-trial-related legal matters were not expected by management to have a material adverse impact.
Important facts for investors to verify
- Progress and outcomes of ACT DMD and ACT CF, including whether results support continued authorization or additional regulatory filings.
- Country-by-country launch timing, reimbursement decisions, pricing and actual paid early-access and commercial sales.
- Cash burn, expense growth and whether the stated late-2017 funding runway remains valid against management’s assumptions.
- Regulatory follow-through on conditional authorization, FDA submission plans, and remediation of the disclosed GCP inspection findings.
- Potential clinical safety signals, commercial supply readiness, and any material changes in financing needs or share dilution.